Teratogenic Effects of Pregabalin in Mice

Document Type: Original Article


1 Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

2 Department of Anatomy, Birjand University of Medical Sciences, Birjand, Iran 3 Medical Toxicology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

3 Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.Departments of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

4 Departments of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

5 Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.Medical Toxicology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran 4 Departments of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran



Anti-epileptic drugs (AEDs) have the potential to affect fetal development throughout pregnancy. Considering the broad therapeutic indications of pregabalin (PGB), its potential teratogenic effects and the levels of homocysteine have been studied.
Materials and Methods:
Timed-pregnant mice received one of three doses of PGB (20, 40 or 80 mg/kg/day) or the vehicle control during organogenesis, intraperitoneally. The litters were stained and examined for malformations. Total homocysteine (tHcy) was measured in serum from the pregnant mice on GD18.
The rate of fetus malformations increased significantly in all treated groups as compared to the control group. The abnormalities included limb, vertebral column and craniofacial abnormalities. The most common abnormality was limb deformity. The percentage of fetal resorption significantly increased at higher doses. There was no significant difference in tHcy concentrations between the treated and control groups.
Pregabalin may have potential teratogenic effects even in lower doses, however with less intensity than other AEDs. Therefore, it is suggested that great caution should be taken when prescribing it in pregnancy and further investigation for possible mechaninsms.


1. Barrett C, Richens A. Epilepsy and pregnancy: report of an epilepsy research foundation workshop. Epilepsy Res 2003; 52:147-187.

2. LaRoche SM. A new look at the second-generation antiepileptic drugs: a decade of experience. Neurologist 2007; 13:133-139.

3. O'Brien MD, Gilmour-White SK. Management of epilepsy in women. Postgrad Med J 2005; 81:78-85.

4. Meador KJ. Effects of in utero antiepileptic drug exposure. Epilepsy Curr 2008; 8:143-117.

5. Perucca E. Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurolo 2005; 4:781-786.

6. Annegers JF, Hauser WA, Elveback LR. Congenital malformations and seizure disorders in the offspring of parents with epilepsy. J Epidemiol 1978; 7:241-247.

7. Palmieri C, Canger R. Teratogenic potential of the newer antiepileptic drugs. CNS Drugs 2002; 16:755- 764.

8. Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77:193-198.

9. Di Guilmi MN, Urbano FJ, Inchauspe CG, Uchitel OD. Pregabalin modulation of neurotransmitter release is mediated by change in intrinsic activation/inactivation properties of ca(v)2.1 calcium channels. J Pharmacol Exp Ther 2010; 336:973-982.

10. Freynhagen R, Grond S, Schupfer G, Hagebeuker A, Schmelz M, Ziegler D, et al. Efficacy and safety of pregabalin in treatment refractory patients with various neuropathic pain entities in clinical routine. Int J Clin Pract 2007; 61:1989-1996.

11. Anonymous. Lyrica Prescribing Information. USA

:Pfizer Inc; 2004.

12. Afshar M, Golalipoor MJ, Azadeh T. Teratogenic effects of Gabapentin on neural tube and skeletal development in mice. Reprod Toxicol 2007; 24:66-67.

13. Rosenquist TH, Anne Ratashak S, Selhub. J. Homocysteine induces congenital defects of the heart and neural tube: effect of folic acid. Proc Natl Acad Sci USA 1996; 93:15227-15232.

14. Vollset SE, Refsum H, Irgens LM, Emblem BM, Tverdal A, Gjessing HK, et al. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine study. Am J Clin Nutr 2000; 71:962-968.

15. Kimmel CA, Trammell C. A rapid procedure for routine double staining of cartilage and bone in fetal and adult animals. Stain Technol 1981; 56:271-273.

16. Vartanian MG, Radulovic LL, Kinsora JJ, Serpa KA, Vergnes M, Bertram E, et al. Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res 2006; 68:189-205.

17. Tassone DM, Boyce E, Guyer J, Nuzum D. Pregabalin: A novel [gamma]-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 2007; 29:26-48.

18. Hoppe C, Rademacher M, Hoffmann JM, Schmidt D, Elger CE. Bodyweight gain under pregabalin therapy in epilepsy: mitigation by counseling patients? Seizure 2008; 17:327-332.

19. Schaefer C, P.W.J. P, Miller RK. Antiepileptics. In: Robert-Gnansia E, Schaefer C, editors. Drug during pregnancy and lactation treatment options and risk assessment. 2

nd ed. Amsrerdam: Elsevier; 2007. p. 255-286.

20. Shorvan S. Handbook of epilepsy treatment. 2nd ed. UK: Blackwell; 2005.

21. Prakash, Prabhu LV, Rai R, Pai MM, Yadav SK, Madhyastha S, et al. Teratogenic effects of the anticonvulsant gabapentin in mice. Singapore Med J 2008 ;49:47-53.

22. Joshi I, Taylor CP. Pregabalin action at a model synapse: binding to presynaptic calcium channel alpha2-delta subunit reduces neurotransmission in mice. Eur J Pharmacol 2006; 553:82-88.

23. Weiss N, Ivanova E. Does the voltage-gated calcium channel alpha2delta-1 subunit play a dual function in skeletal muscle? J Physiol 2008; 586:2035-2037.

24. Afshar M, Hassanzadeh-Taheri MM, Moallem SA, Tamizi A, Golalipour MJ. Teratogenic effects of gabapentin on the skeletal system of BALB/c mice fetuses. Neurosciences 2009; 14:239-244.

25. Engel J, Pedley TA, Aicardi J. Epilepsy: A Comprehensive Textbook. 2

nd ed. Philadelphia: Wolter Kluwer; 2008.

26. Zhang T, Xin R, Gu X, Wang F, Pei L, Lin L, et al. Maternal serum vitamin B

12, folate and homocysteine and the risk of neural tube defects in the offspring in a high-risk area of China. Public Health Nutr 2009; 12:680-686.

27. Seshadri S, Beiser A, Selhub J, Jacques P, Rosenberg I, D'Agostino R, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346:476-483.

28. Jacobsen DW. Homocysteine and vitamins in cardiovascular disease. Clin Chem 1998; 44:1833-1843.

29. Dehghani Dolatabadi HR, Reisi P, Alaei H, Azizi Malekabadi H, Pilehvarian AS. Folic Acid and coenzyme Q

10 ameliorate cognitive dysfunction in the rats with intracerebroventricular injection of streptozotocin. Iran J Basic Med Sci 2012; 15:719-724.

30. Sikora J, Magnucki J, Ziętek J, Kobielska L, Partyka R, Kokocinska D, et al. Homocysteine, folic acid and vitamin B12 concentration in patients with recurrent miscarriages. Neuroendocrino Lett 2007; 28:507-512.

31. Schwaninger M, Ringleb P, Winter R, Kohl B, Fiehn W, Rieser PA, et al. Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. Epilepsia 1999; 40:345-350.